{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:19:06Z","timestamp":1770347946976,"version":"3.49.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004364","name":"BP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.dsx.2023.102790","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T11:38:42Z","timestamp":1685792322000},"page":"102790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review"],"prefix":"10.1016","volume":"17","author":[{"given":"Swetha R.","family":"Reghunath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viji Pulikkel","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Thunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.N.","family":"Shivashankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leelavathi D.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4093\/dmj.2016.40.3.230","article-title":"Comparison of vildagliptin and pioglitazone in Korean patients with type 2 diabetes inadequately controlled with metformin","volume":"40","author":"Kim","year":"2016","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.dsx.2023.102790_bib2","year":"2021"},{"issue":"2","key":"10.1016\/j.dsx.2023.102790_bib3","first-page":"229","article-title":"Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week randomized clinical trial","volume":"8","author":"Wang","year":"2016","journal-title":"J\u00a0Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib4","doi-asserted-by":"crossref","first-page":"e1753","DOI":"10.7717\/peerj.1753","article-title":"Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model","volume":"4","author":"Narushima","year":"2016","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib5","first-page":"237","article-title":"Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study","volume":"6","author":"Chatterjee","year":"2014","journal-title":"J\u00a0Diabetes"},{"issue":"6","key":"10.1016\/j.dsx.2023.102790_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00592-018-1271-3","article-title":"Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"56","author":"Sesti","year":"2019","journal-title":"Acta Diabetol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102790_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharmaceut J"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13300-014-0059-x","article-title":"Efficacy and safety of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes mellitus","volume":"5","author":"Odawara","year":"2014","journal-title":"Diabetes Ther"},{"issue":"12","key":"10.1016\/j.dsx.2023.102790_bib10","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dsx.2023.102790_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40264-013-0077-z","article-title":"Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto prefecture","volume":"36","author":"Kajiwara","year":"2013","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s12325-019-01189-w","article-title":"Long-term, real-world safety and efficacy of teneligliptin: a post-marketing surveillance of more than 10,000 patients with type 2 diabetes in Japan","volume":"37","author":"Kadowaki","year":"2020","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3391","article-title":"Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Yang","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s12020-015-0841-1","article-title":"Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes","volume":"52","author":"Bekiari","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.dsx.2023.102790_bib15","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.dsx.2023.102790_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14740338.2020.1740679","article-title":"Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan","volume":"19","author":"Ishida","year":"2020","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.dsx.2023.102790_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMAScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2007","journal-title":"Int J Soc Res Methodol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","article-title":"Guidance for conducting systematic scoping reviews","volume":"13","author":"Peters","year":"2015","journal-title":"Int J Evid Base Healthc"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Base Healthc"},{"key":"10.1016\/j.dsx.2023.102790_bib21","series-title":"JBI manual for evidence synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.dsx.2023.102790_bib22","series-title":"Joanna Briggs Institute reviewer's manual","first-page":"3","article-title":"Systematic reviews of effectiveness","author":"Tufanaru","year":"2017"},{"issue":"5","key":"10.1016\/j.dsx.2023.102790_bib23","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s12325-020-01306-0","article-title":"Long-term safety and efficacy of teneligliptin in elderly patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance in Japan","volume":"37","author":"Kadowaki","year":"2020","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s13300-018-0416-2","article-title":"Safety and efficacy of teneligliptin in patients with type 2 diabetes mellitus and impaired renal function: interim report from post-marketing surveillance","volume":"9","author":"Haneda","year":"2018","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.dsx.2023.102790_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14656566.2017.1420165","article-title":"Safety and efficacy of long-term treatment with teneligliptin: interim analysis of a post marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus","volume":"19","author":"Kadowaki","year":"2018","journal-title":"Expet Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.dsx.2023.102790_bib26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/dom.14317","article-title":"Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: a post marketing surveillance study","volume":"23","author":"Bae","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13300-019-00723-x","article-title":"Long-term safety and effectiveness of linagliptin in Japanese patients with type 2 diabetes mellitus: a 3-year post-marketing surveillance study","volume":"11","author":"Yamamoto","year":"2020","journal-title":"Diabetes Ther"},{"issue":"4","key":"10.1016\/j.dsx.2023.102790_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/pds.4733","article-title":"Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: population-based cohort and nested case\u2013control studies","volume":"28","author":"Wang","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.dsx.2023.102790_bib29","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/dc22-0712","article-title":"Incretin-based drugs and the risk of acute liver injury among patients with type 2 diabetes","volume":"45","author":"Pradhan","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17366-x","article-title":"Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)","volume":"12","author":"Ohyama","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3803\/EnM.2015.30.3.263","article-title":"Diabetes in Asians","volume":"30","author":"Rhee","year":"2015","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"6","key":"10.1016\/j.dsx.2023.102790_bib32","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/dom.13242","article-title":"Effect of race on the glycaemic response to sitagliptin: insights from the trial evaluating cardiovascular outcomes with sitagliptin (TECOS)","volume":"20","author":"Davis","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1464-5491.2007.02341.x","article-title":"Hypoglycaemia in type 2 diabetes","volume":"25","author":"Amiel","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2023.102790_bib34","article-title":"Gastrointestinal tract disorders in older age","volume":"2019","author":"Dumic","year":"2019","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.dsx.2023.102790_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/894087","article-title":"Decreased gastric motility in type II diabetic patients","volume":"2014","author":"Chiu","year":"2014","journal-title":"BioMed Res Int"},{"issue":"9","key":"10.1016\/j.dsx.2023.102790_bib36","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.clinthera.2017.07.036","article-title":"Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis","volume":"39","author":"Wu","year":"2017","journal-title":"Clin Therapeut"},{"issue":"2","key":"10.1016\/j.dsx.2023.102790_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.dsx.2023.102790_bib38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2018.08.030","article-title":"Prevalence estimates for pemphigoid in the United States: a sex-adjusted and age-adjusted population analysis","volume":"80","author":"Wertenteil","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.dsx.2023.102790_bib40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00002512-199404060-00002","article-title":"Polypharmacy in the aged. Practical solutions","volume":"4","author":"Stewart","year":"1994","journal-title":"Drugs Aging"},{"issue":"11","key":"10.1016\/j.dsx.2023.102790_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112133","article-title":"Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in karachi: a prospective cohort study","volume":"9","author":"Ahmed","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2023.102790_bib42","series-title":"In-depth answers- medication safety - drug interactions (single)","year":"2022"},{"key":"10.1016\/j.dsx.2023.102790_bib43","series-title":"In-depth answers- medication safety - drug interactions (single)","year":"2022"},{"key":"10.1016\/j.dsx.2023.102790_bib44","series-title":"In-depth answers- medication safety - drug interactions (single)","year":"2022"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib46","first-page":"1","article-title":"Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus","volume":"12","author":"Yu","year":"2020","journal-title":"Diabetol Metab Syndrome"},{"key":"10.1016\/j.dsx.2023.102790_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74000-4","article-title":"Gender differences in adverse event reports associated with antidiabetic drugs","volume":"10","author":"Joung","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.dsx.2023.102790_bib49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2169\/internalmedicine.50.5057","article-title":"A\u00a0case of drug-induced hepatic injury associated with sitagliptin","volume":"50","author":"Toyoda-Akui","year":"2011","journal-title":"Intern Med"},{"issue":"6","key":"10.1016\/j.dsx.2023.102790_bib50","article-title":"Acute liver injury induced by sitagliptin: report of two cases and review of literature","volume":"10","author":"Shahbaz","year":"2018","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12072-020-10122-1","article-title":"Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan","volume":"15","author":"Yen","year":"2021","journal-title":"Hepatol Int"},{"issue":"8","key":"10.1016\/j.dsx.2023.102790_bib52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","article-title":"Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic","volume":"24","author":"De Valle","year":"2006","journal-title":"Aliment Pharmacol Therapeut"},{"issue":"8","key":"10.1016\/j.dsx.2023.102790_bib53","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1590-8658(00)80336-9","article-title":"Spontaneous reporting of drug-related hepatic reactions from two Italian regions (Lombardy and Veneto)","volume":"32","author":"Conforti","year":"2000","journal-title":"Dig Liver Dis"},{"issue":"1028","key":"10.1016\/j.dsx.2023.102790_bib54","first-page":"315","article-title":"Drug associated hepatic reactions in New Zealand: 21 years experience","volume":"109","author":"Pillans","year":"1996","journal-title":"N\u00a0Z Med J"},{"issue":"6","key":"10.1016\/j.dsx.2023.102790_bib55","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a US multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.dsx.2023.102790_bib56","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1177\/0960327113512860","article-title":"Female gender as a susceptibility factor for drug-induced liver injury","volume":"33","author":"Amacher","year":"2014","journal-title":"Hum Exp Toxicol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102790_bib57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","article-title":"How important are gender differences in pharmacokinetics?","volume":"41","author":"Meibohm","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib58","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-6823-8-14","article-title":"Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis","volume":"8","author":"Williams-Herman","year":"2008","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"10.1016\/j.dsx.2023.102790_bib60","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.jaip.2020.03.015","article-title":"Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: a disproportionality analysis of the WHO pharmacovigilance database","volume":"8","author":"Lepelley","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12948-021-00164-7","article-title":"Angioedema associated with dipeptidyl peptidase-IV inhibitors","volume":"19","author":"Cassano","year":"2021","journal-title":"Clin Mol Allergy"},{"issue":"4","key":"10.1016\/j.dsx.2023.102790_bib62","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1111\/dme.12134","article-title":"Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?","volume":"30","author":"Saisho","year":"2013","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.dsx.2023.102790_bib63","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jaip.2019.02.008","article-title":"Angioedema following initiation of glecaprevir\/pibrentasvir while on sitagliptin","volume":"7","author":"Schneider","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib64","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.ijcard.2013.07.257","article-title":"The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin","volume":"168","author":"Hamasaki","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102790_bib65","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2010.02973.x","article-title":"Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report","volume":"27","author":"Skalli","year":"2010","journal-title":"Diabet Med"},{"issue":"8","key":"10.1016\/j.dsx.2023.102790_bib66","doi-asserted-by":"crossref","DOI":"10.2337\/dc12-0574","article-title":"Sitagliptin-associated angioedema","volume":"35","author":"Gosmanov","year":"2012","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.dsx.2023.102790_bib67","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.dsx.2023.102790_bib68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00403-017-1778-4","article-title":"Incidence of bullous pemphigoid in Sweden 2005\u20132012: a nationwide population-based cohort study of 3761 patients","volume":"309","author":"Thorslund","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.dsx.2023.102790_bib69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0190-9622(99)70061-7","article-title":"Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence","volume":"41","author":"Jung","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.dsx.2023.102790_bib70","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7","key":"10.1016\/j.dsx.2023.102790_bib71","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in The Netherlands: an explorative observational study","volume":"85","author":"de Vries","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib72","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.4155","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden","volume":"26","author":"Holm","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.dsx.2023.102790_bib73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.dsx.2023.102790_bib74","article-title":"Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"Clin Med"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-021-00377-0","article-title":"Sex differences associated with adverse drug reactions resulting in hospital admissions","volume":"12","author":"Hendriksen","year":"2021","journal-title":"Biol Sex Differ"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"9","key":"10.1016\/j.dsx.2023.102790_bib77","first-page":"509","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes","volume":"35","author":"Pathak","year":"2010","journal-title":"P\u00a0T"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2125.2007.03031.x","article-title":"The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers","volume":"65","author":"He","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dsx.2023.102790_bib79","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/14740338.2016.1236909","article-title":"Adverse safety events in patients with chronic kidney disease (CKD)","volume":"15","author":"Offurum","year":"2016","journal-title":"Expet Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.dsx.2023.102790_bib80","first-page":"OE05","article-title":"Teneligliptin in management of diabetic kidney disease: a review of place in therapy","volume":"11","author":"Abubaker","year":"2017","journal-title":"J\u00a0Clin Diagn Res"},{"issue":"2","key":"10.1016\/j.dsx.2023.102790_bib81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11255-013-0552-6","article-title":"Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes","volume":"46","author":"Otsuki","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102790_bib82","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc12-1365","article-title":"Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency","volume":"36","author":"Arjona Ferreira","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.dsx.2023.102790_bib83","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2215\/CJN.08890620","article-title":"Adverse drug effects in patients with CKD","volume":"15","author":"Perazella","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.dsx.2023.102790_bib84","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2215\/CJN.01030120","article-title":"Adverse drug reactions in patients with CKD","volume":"15","author":"Laville","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2042018813486165","article-title":"Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors","volume":"4","author":"Gallwitz","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"Suppl 2","key":"10.1016\/j.dsx.2023.102790_bib86","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.2337\/dc09-S315","article-title":"Incretin-based therapies: viewpoints on the way to consensus","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2023.102790_bib87","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/2042098614523031","article-title":"Safety of dipeptidyl peptidase 4 inhibitors: a perspective review","volume":"5","author":"Karagiannis","year":"2014","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"10.1016\/j.dsx.2023.102790_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dsx.2023.102790_bib89","series-title":"In-depth answers- drug interactions results","year":"2022"},{"issue":"2","key":"10.1016\/j.dsx.2023.102790_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0262","article-title":"Analysis of severe hypoglycemia among adults with type 2 diabetes and non-alcoholic fatty liver disease","volume":"5","author":"Lee","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dsx.2023.102790_bib91","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s40064-015-1135-z","article-title":"Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury","volume":"4","author":"Asakawa","year":"2015","journal-title":"SpringerPlus"},{"issue":"4","key":"10.1016\/j.dsx.2023.102790_bib92","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"112","key":"10.1016\/j.dsx.2023.102790_bib93","first-page":"2103","article-title":"Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus","volume":"58","author":"Iwasaki","year":"2011","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.dsx.2023.102790_bib94","first-page":"1662","article-title":"DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus","volume":"20","author":"Kanazawa","year":"2014","journal-title":"Med Sci Mon Int Med J Exp Clin Res"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123000863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123000863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:23:37Z","timestamp":1761729817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123000863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1871402123000863"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102790","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102790"}}